Since iron is required for neurotransmitter synthesis, decreased iron stores can result in lower biogenic amine production, as seen in Fibromyalgia (FM) patients.
The goals are to look into the connection between iron deficiency anemia (IDA) and FM, as well as the effects of various interventions.
We used the Taiwan National Health Insurance Research Database to perform our research.
Around 2000 and 2008, 13,381 patients with newly diagnosed IDA were included in the IDA cohort.
By sex, age, and index year, each patient with IDA was paired with one person without IDA.
The Cox proportional hazards regression analysis was conducted to estimate the association between IDA and FM risk. The event was the occurrence of FM. The overall incidence density rate of FM in the IDA cohort was higher than in the non-IDA cohort with a multivariable Cox proportional hazards model measured adjusted hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.13-1.25). When using non-IDA group as reference, we compared with different therapies for IDA. The adjusted HRs of FM were 1.38 (95% CI = 1.30-1.47), 1.10 (95% CI = 1.03-1.16), 1.18 (95% CI = 0.98-1.43) and 0.73 (95% CI = 0.58-0.90) for IDA patient without therapy, iron supplement alone, blood transfusion alone and both iron supplement and blood transfusion respectively.
Our findings indicate that IDA is linked to a higher risk of FM.
Iron supplementation should be provided to all patients to correct anemia and replenish body stores.
